Sitagliptin effectiveness in the treatment of type 2 diabetes Review article
Article Sidebar
Main Article Content
Abstract
Sitagliptin belongs to the group of dipeptidyl peptidase 4 (DPP-4) inhibitors, known as gliptins, a class of oral antihyperglycemic agents used in the treatment of type 2 diabetes mellitus (T2DM). The mechanism of DPP-4 inhibitors is to block dipeptidyl peptidase 4, increasing incretin levels – glucagon-like peptide 1 and glucose-dependent insulinotropic peptide. It results in an increase of postprandial insulin secretion and inhibition of glucagon release. The cardio-vascular safety and good tolerance of treatment allow us to use this group in T2DM monotherapy or combination therapy with other antihyperglycemic agents, including insulin. According to the recommendations of Diabetes Poland, DPP-4 inhibitors are used at the stage of intensification of T2DM therapy, or in monotherapy when metformin is not tolerated. In the present article, we discuss the indications and benefits from sitagliptin therapy in T2DM.
Article Details
Copyright © by Medical Education. All rights reserved.
References
2. Nauck MA, Meier JJ. Incretin hormones: Their role in health and disease. Diabetes Obes Metab. 2018; 20(Suppl. 1): 5-21.
3. Aschner P, Kipnes MS, Lunceford JK et al.; Sitagliptin Study 021 Group. Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care. 2006; 29(12): 2632-7.
4. Green JB, Bethel MA, Armstrong PW et al.; TECOS Study Group. Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2015; 373(3): 232-42.
5. Enzan N, Matsushima S, Kaku H et al. Beneficial Effects of Dipeptidyl Peptidase-4 Inhibitors on Heart Failure With Preserved Ejection Fraction and Diabetes. JACC Asia. 2023; 3(1): 93-104.
6. Scott LJ. Sitagliptin: A Review in Type 2 Diabetes. Drugs. 2017; 77(2): 209-24.
7. Zaccardi F, Jacquot E, Cortese V et al. Comparative effectiveness of gliclazide modified release versus sitagliptin as second-line treatment after metformin monotherapy in patients with uncontrolled type 2 diabetes. Diabetes Obes Metab. 2020; 22(12): 2417-26.
8. Zhang Y, Hong J, Chi J et al. Head-to-head comparison of dipeptidyl peptidase-IV inhibitors and sulfonylureas – a meta-analysis from randomized clinical trials. Diabetes Metab Res Rev. 2014; 30(3): 241-56.
9. Sakura H, Hashimoto N, Sasamoto K et al. Effect of sitagliptin on blood glucose control in patients with type 2 diabetes mellitus who are treatment naive or poorly responsive to existing antidiabetic drugs: the JAMP study. BMC Endocr Disord. 2016; 16(1): 70.
10. Charakterystyka Produktu Leczniczego. Sitagliptyna Aurovitas.
11. Raz I, Hanefeld M, Xu L et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus. Diabetologia. 2006; 49: 2564-71.
12. Tsapas A, Karagiannis T, Kakotrichi P et al. Comparative efficacy of glucose-lowering medications on body weight and blood pressure in patients with type 2 diabetes: A systematic review and network meta-analysis. Diabetes Obes Metab. 2021; 23(9): 2116-24.
13. Frias JP, Zimmer Z, Lam RLH et al. Double-blind, randomized clinical trial assessing the efficacy and safety of early initiation of sitagliptin during metformin uptitration in the treatment of patients with type 2 diabetes: The CompoSIT-M study. Diabetes Obes Metab. 2019; 21(5): 1128-35.
14. Derosa G, D’Angelo A, Maffioli P. Sitagliptin in type 2 diabetes mellitus: Efficacy after five years of therapy. Pharmacol Res. 2015; 100: 127-34.
15. Vashisht R, Jung K, Schuler A et al. Association of Hemoglobin A1c Levels With Use of Sulfonylureas, Dipeptidyl Peptidase 4 Inhibitors, and Thiazolidinediones in Patients With Type 2 Diabetes Treated With Metformin: Analysis From the Observational Health Data Sciences and Informatics Initiative. JAMA Netw Open. 2018; 1(4): e181755.
16. Shankar RR, Bao Y, Han P et al. Sitagliptin added to stable insulin therapy with or without metformin in Chinese patients with type 2 diabetes. J Diabetes Investig. 2017; 8(3): 321-9.